Press Releases April 30, 2026 08:00 AM

Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Lexicon Pharmaceuticals Schedules Q1 2026 Earnings Release and Conference Call for May 7, 2026

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
LXRX

Lexicon Pharmaceuticals, a biopharmaceutical company focused on pioneering medicines for neuropathic pain, cardiometabolic diseases, and obesity, announced it will report its first quarter 2026 financial results on May 7, 2026, prior to market open. The company will also host a conference call and webcast to discuss the results and provide a business update.

Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
LXRX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Lexicon will release Q1 2026 financial results before market open on May 7, 2026.
  • A management conference call and webcast will be held to discuss the earnings and company updates.
  • The company has an active pipeline targeting neuropathic pain, hypertrophic cardiomyopathy, obesity, and metabolic disorders.
  • The announcement highlights Lexicon's ongoing development in the biopharmaceutical sector, particularly in cardiometabolic and metabolic disease areas.

THE WOODLANDS, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2026 financial results on Thursday, May 7, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update. 

Participants can access the conference call live via webcast on the Events page of the Company’s website at https://investors.lexpharma.com/. Participants who wish to ask a question may join by phone at 800-715-9871 and use passcode 9826247. An archived version of the webcast will be available on the Lexicon website.  

About Lexicon Pharmaceuticals  
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit www.lexpharma.com.   

For Investor and Media Inquiries:  
Lisa DeFrancesco   
Lexicon Pharmaceuticals, Inc.  
lexinvest@lexpharma.com  


Risks

  • Financial results may fall short of market expectations, impacting stock price.
  • Pipeline drug candidates are in various stages of development, which carries inherent clinical and regulatory risks.
  • Market sentiment may remain cautious awaiting detailed financial and operational updates following the release.

More from Press Releases

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026 Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026